IL189617A - Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors - Google Patents
Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptorsInfo
- Publication number
- IL189617A IL189617A IL189617A IL18961708A IL189617A IL 189617 A IL189617 A IL 189617A IL 189617 A IL189617 A IL 189617A IL 18961708 A IL18961708 A IL 18961708A IL 189617 A IL189617 A IL 189617A
- Authority
- IL
- Israel
- Prior art keywords
- quinolin
- dihydro
- dimethyl
- ylethynyl
- phenylethynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2005/003285 WO2007023242A1 (fr) | 2005-08-24 | 2005-08-24 | Tétrahydroquinolinones et leur usage en tant que modulateurs des récepteurs de glutamate métabotropiques |
PCT/GB2006/003170 WO2007023290A1 (fr) | 2005-08-24 | 2006-08-24 | Tétrahydroquinolinones et leur utilisation comme modulateurs de récepteurs métabotropique de glutamate |
Publications (2)
Publication Number | Publication Date |
---|---|
IL189617A0 IL189617A0 (en) | 2008-06-05 |
IL189617A true IL189617A (en) | 2012-08-30 |
Family
ID=36273537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL189617A IL189617A (en) | 2005-08-24 | 2008-02-19 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1931635A1 (fr) |
JP (1) | JP2009506018A (fr) |
KR (1) | KR20080031972A (fr) |
CN (1) | CN101223142A (fr) |
AR (1) | AR056044A1 (fr) |
AU (1) | AU2006283359B2 (fr) |
BR (1) | BRPI0615059A2 (fr) |
CA (1) | CA2610873C (fr) |
EA (1) | EA200800660A1 (fr) |
IL (1) | IL189617A (fr) |
MX (1) | MX2008001871A (fr) |
NO (1) | NO20081428L (fr) |
TW (1) | TWI329635B (fr) |
WO (2) | WO2007023242A1 (fr) |
ZA (1) | ZA200710668B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
EP2513118B1 (fr) * | 2009-12-18 | 2013-09-18 | Janssen Pharmaceutica, N.V. | Thiazoles bicycliques en tant que modulateurs allostériques de récepteurs mGluR5 |
CA2782950A1 (fr) * | 2009-12-18 | 2011-06-23 | Janssen Pharmaceutica Nv | Thiazoles bicycliques en tant que modulateurs allosteriques des recepteurs mglur5 |
WO2011092293A2 (fr) | 2010-02-01 | 2011-08-04 | Novartis Ag | Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf |
JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体 |
WO2011095450A1 (fr) | 2010-02-02 | 2011-08-11 | Novartis Ag | Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf |
WO2012052451A1 (fr) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Modulateurs des récepteurs métabotropes au glutamate |
WO2012139876A1 (fr) | 2011-04-14 | 2012-10-18 | Merz Pharma Gmbh & Co. Kgaa | Formulations entériques de modulateurs de récepteur de glutamate métabotropique |
WO2012172093A1 (fr) * | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate |
WO2013050527A1 (fr) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Dérivés de quinazoline en tant qu'inhibiteurs de l'enzyme pde10a |
EP2650284A1 (fr) * | 2012-04-10 | 2013-10-16 | Merz Pharma GmbH & Co. KGaA | Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique |
KR101418078B1 (ko) * | 2013-01-23 | 2014-07-10 | 한국과학기술연구원 | mGluR5 길항제로서의 2-(치환된에티닐)퀴놀린 유도체 |
KR20160110357A (ko) * | 2013-11-15 | 2016-09-21 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | Ebna1 억제제 및 그의 사용 방법 |
KR101579496B1 (ko) * | 2014-07-03 | 2015-12-23 | 한국과학기술연구원 | mGluR5의 표식용 방사성 조성물 |
EP3285582B1 (fr) | 2015-03-26 | 2020-11-11 | Merck Sharp & Dohme Corp. | Dérivés de quinolizine substitués par un phosphate utiles en tant qu'inhibiteurs de l'intégrase du vih |
WO2016183534A1 (fr) | 2015-05-14 | 2016-11-17 | The Wistar Institute Of Anatomy And Biology | Inhibiteurs d'ebna1 et méthodes les utilisant |
HUE045546T2 (hu) | 2015-06-03 | 2020-01-28 | Bristol Myers Squibb Co | 4-hidroxi-3-(heteroaril)piridin-2-on APJ agonisták felhasználásra cardiovascularis megbetegedések kezelésében |
EP3459939A1 (fr) * | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Nouveaux composés hétérocycliques comme modulateurs de mglur7 |
EP3793546A4 (fr) | 2018-05-17 | 2021-12-08 | The Wistar Institute | Formes cristallines d'inhibiteur d'ebna1 et procédés de préparation et méthodes d'utilisation de celles-ci |
CA3155209A1 (fr) | 2019-10-21 | 2021-04-29 | Chan Mi Joung | Utilisation de composes d'imidazopyrimidine ou d'imidazotriazine pour la prevention, le soulagement ou le traitement de troubles cognitifs, ou pour ameliorer la fonction cognitive |
KR20220086607A (ko) * | 2019-10-21 | 2022-06-23 | 에스케이바이오팜 주식회사 | 발달 장애의 예방, 경감 또는 치료를 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001293847B2 (en) * | 2000-10-02 | 2007-05-24 | Janssen Pharmaceutica N.V. | Metabotropic glutamate receptor antagonists |
TWI301760B (en) * | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
-
2005
- 2005-08-24 WO PCT/GB2005/003285 patent/WO2007023242A1/fr active Application Filing
-
2006
- 2006-08-21 TW TW095130667A patent/TWI329635B/zh not_active IP Right Cessation
- 2006-08-24 CA CA2610873A patent/CA2610873C/fr not_active Expired - Fee Related
- 2006-08-24 JP JP2008527513A patent/JP2009506018A/ja active Pending
- 2006-08-24 AR ARP060103692A patent/AR056044A1/es unknown
- 2006-08-24 WO PCT/GB2006/003170 patent/WO2007023290A1/fr active Application Filing
- 2006-08-24 CN CNA2006800260106A patent/CN101223142A/zh active Pending
- 2006-08-24 BR BRPI0615059-4A patent/BRPI0615059A2/pt not_active IP Right Cessation
- 2006-08-24 MX MX2008001871A patent/MX2008001871A/es active IP Right Grant
- 2006-08-24 AU AU2006283359A patent/AU2006283359B2/en not_active Ceased
- 2006-08-24 KR KR1020087004382A patent/KR20080031972A/ko not_active Application Discontinuation
- 2006-08-24 EA EA200800660A patent/EA200800660A1/ru unknown
- 2006-08-24 EP EP06779201A patent/EP1931635A1/fr not_active Withdrawn
-
2007
- 2007-12-06 ZA ZA200710668A patent/ZA200710668B/xx unknown
-
2008
- 2008-02-19 IL IL189617A patent/IL189617A/en not_active IP Right Cessation
- 2008-03-18 NO NO20081428A patent/NO20081428L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1931635A1 (fr) | 2008-06-18 |
WO2007023290A1 (fr) | 2007-03-01 |
TWI329635B (en) | 2010-09-01 |
AU2006283359A1 (en) | 2007-03-01 |
BRPI0615059A2 (pt) | 2011-04-26 |
AU2006283359B2 (en) | 2010-05-27 |
KR20080031972A (ko) | 2008-04-11 |
AR056044A1 (es) | 2007-09-12 |
WO2007023242A1 (fr) | 2007-03-01 |
CA2610873C (fr) | 2010-08-03 |
NO20081428L (no) | 2008-03-18 |
TW200728283A (en) | 2007-08-01 |
ZA200710668B (en) | 2009-08-26 |
IL189617A0 (en) | 2008-06-05 |
MX2008001871A (es) | 2008-04-09 |
CA2610873A1 (fr) | 2007-03-01 |
JP2009506018A (ja) | 2009-02-12 |
CN101223142A (zh) | 2008-07-16 |
EA200800660A1 (ru) | 2008-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2610873C (fr) | Tetrahydroquinolinones et leur utilisation comme modulateurs de recepteurs metabotropique de glutamate | |
US20080032998A1 (en) | Pyrazolopyrimidines, a process for their preparation and their use as medicine | |
US20110003820A1 (en) | Pyrazolopyrimidines, a process for their preparation and their use as medicine | |
CA2556653C (fr) | Tetrahydroquinolinones et leur utilisation comme antagonistes des recepteurs de glutamate metabotropique | |
US20120178742A1 (en) | Metabotropic glutamate receptor modulators | |
EP1957475A1 (fr) | Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate | |
US20070299113A1 (en) | Metabotropic glutamate receptor modulators | |
WO2007023245A1 (fr) | Tetrahydroquinolinones et leur utilisation en tant que modulateurs des recepteurs metabotropes du glutamate | |
WO2012085166A1 (fr) | Modulateurs des récepteurs glutamatergiques métabotropes | |
US7550482B2 (en) | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | |
US20060004001A1 (en) | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | |
WO2008035049A1 (fr) | Adamantanyl-(cyclopropyl)-cétones utilisées en tant que modulateurs du récepteur métabotropique du glutamate | |
WO2012152854A1 (fr) | Modulateurs de récepteur de glutamate métabotropique | |
MXPA06009564A (en) | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
MM9K | Patent not in force due to non-payment of renewal fees |